Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) EBT Margin (2016 - 2025)

Guided Therapeutics' EBT Margin history spans 16 years, with the latest figure at 206.44% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 6499356.0% to 206.44% in Q4 2025 year-over-year; TTM through Dec 2025 was 416.95%, a 3411162.0% increase, with the full-year FY2025 number at 416.69%, up 3411188.0% from a year prior.
  • EBT Margin hit 206.44% in Q4 2025 for Guided Therapeutics, up from 1236.67% in the prior quarter.
  • Over the last five years, EBT Margin for GTHP hit a ceiling of 357.89% in Q3 2021 and a floor of 65200.0% in Q4 2024.
  • Historically, EBT Margin has averaged 14300.47% across 5 years, with a median of 3744.32% in 2023.
  • Biggest five-year swings in EBT Margin: crashed -6399375bps in 2024 and later surged 6499356bps in 2025.
  • Tracing GTHP's EBT Margin over 5 years: stood at 740.0% in 2021, then crashed by -4864bps to 36733.33% in 2022, then skyrocketed by 97bps to 1206.25% in 2023, then plummeted by -5305bps to 65200.0% in 2024, then surged by 100bps to 206.44% in 2025.
  • Business Quant data shows EBT Margin for GTHP at 206.44% in Q4 2025, 1236.67% in Q3 2025, and 693.16% in Q2 2025.